
Reset all filters
01 1Cozaar
02 13Cozaar/Hyzaar
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2020 Revenue in Millions : 386
2019 Revenue in Millions : 442
Growth (%) : -13
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 357
2020 Revenue in Millions : 386
Growth (%) : -8
Main Therapeutic Indication : Cardiovascular Diseases
Currency : USD
2021 Revenue in Millions : 357
2020 Revenue in Millions : 386
Growth (%) : -8
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 323
2021 Revenue in Millions : 357
Growth (%) : -10
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2022 Revenue in Millions : 323
2021 Revenue in Millions : 357
Growth (%) : -10
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 281
2022 Revenue in Millions : 323
Growth (%) : -13
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2023 Revenue in Millions : 281
2022 Revenue in Millions : 323
Growth (%) : -13
Losartan/Losartan Potassium Hydrochlorothiazide
Main Therapeutic Indication : Cardiology/Vascular Diseases
Currency : USD
2024 Revenue in Millions : 243
2023 Revenue in Millions : 281
Growth (%) : -14
Losartan and Hydrochlorothiazide
Main Therapeutic Indication : Antihypertensives
Currency : USD
2015 Revenue in Millions : 806
2014 Revenue in Millions : 667
Growth (%) : -17%
Losartan and Hydrochlorothiazide
Main Therapeutic Indication : Antihypertensives
Currency : USD
2014 Revenue in Millions : -19.90%
2013 Revenue in Millions :
Growth (%) :